Gyre Therapeutics Stock Shares Owned By Insiders
| GYRE Stock | 11.75 1.16 8.99% |
Gyre Therapeutics fundamentals help investors to digest information that contributes to Gyre Therapeutics' financial success or failures. It also enables traders to predict the movement of Gyre Stock. The fundamental analysis module provides a way to measure Gyre Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gyre Therapeutics stock.
Gyre | Shares Owned By Insiders |
Gyre Therapeutics Company Shares Owned By Insiders Analysis
Gyre Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Gyre Therapeutics Shares Owned By Insiders | 74.70 % |
Most of Gyre Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gyre Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gyre Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Gyre Therapeutics is extremely important. It helps to project a fair market value of Gyre Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Gyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 74% of Gyre Therapeutics are shares owned by insiders. This is 392.12% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Gyre Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gyre Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gyre Therapeutics could also be used in its relative valuation, which is a method of valuing Gyre Therapeutics by comparing valuation metrics of similar companies.Gyre Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Gyre Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Gyre Therapeutics from analyzing Gyre Therapeutics' financial statements. These drivers represent accounts that assess Gyre Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gyre Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.2B | 1.8B | 418.2M | 610.1M | 1.6B | 2.3B | |
| Enterprise Value | 1.2B | 1.8B | 376.3M | 588.4M | 1.5B | 2.2B |
Gyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Gyre Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 85.82 M | ||||
| Shares Owned By Insiders | 74.70 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 376.58 K | ||||
| Price To Book | 17.54 X | ||||
| Price To Sales | 9.93 X | ||||
| Revenue | 113.45 M | ||||
| EBITDA | 20.33 M | ||||
| Net Income | (85.48 M) | ||||
| Total Debt | 409 K | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | 25.89 M | ||||
| Short Ratio | 11.66 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Number Of Employees | 593 | ||||
| Market Capitalization | 1.11 B | ||||
| Total Asset | 116.54 M | ||||
| Retained Earnings | (85.54 M) | ||||
| Working Capital | 37.17 M | ||||
| Net Asset | 116.54 M |
About Gyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out Gyre Therapeutics Piotroski F Score and Gyre Therapeutics Altman Z Score analysis. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.